Amneal Pharmaceuticals, Inc. $AMRX Shares Purchased by Bank of New York Mellon Corp

Bank of New York Mellon Corp boosted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 84.3% during the first quarter, HoldingsChannel.com reports. The firm owned 914,089 shares of the company’s stock after acquiring an additional 418,241 shares during the period. Bank of New York Mellon Corp’s holdings in Amneal Pharmaceuticals were worth $11,362,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Kemnay Advisory Services Inc. purchased a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at $26,000. Federated Hermes Inc. raised its position in shares of Amneal Pharmaceuticals by 1,680.6% in the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after buying an additional 2,168 shares during the period. Comerica Bank raised its position in shares of Amneal Pharmaceuticals by 186.7% in the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after buying an additional 1,957 shares during the period. Spire Wealth Management boosted its holdings in Amneal Pharmaceuticals by 66.6% in the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after acquiring an additional 1,023 shares during the last quarter. Finally, Transamerica Financial Advisors LLC boosted its holdings in Amneal Pharmaceuticals by 541.9% in the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock valued at $37,000 after acquiring an additional 2,460 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Trading Down 1.0%

AMRX opened at $18.32 on Friday. The firm’s 50 day moving average is $16.23 and its 200-day moving average is $14.26. Amneal Pharmaceuticals, Inc. has a 52-week low of $7.66 and a 52-week high of $19.26. The company has a quick ratio of 1.59, a current ratio of 2.20 and a debt-to-equity ratio of 77.65. The firm has a market capitalization of $5.84 billion, a P/E ratio of 37.39 and a beta of 1.26.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. The business had revenue of $722.52 million during the quarter. Analysts expect that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Deborah M. Autor sold 34,819 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $12.94, for a total transaction of $450,557.86. Following the completion of the sale, the director directly owned 93,660 shares in the company, valued at $1,211,960.40. This trade represents a 27.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 17.30% of the stock is currently owned by insiders.

Amneal Pharmaceuticals News Summary

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Q2 results exceeded expectations. Amneal reported revenue of approximately $796 million, GAAP net income of $58 million, adjusted EBITDA of $206 million and adjusted diluted EPS of $0.30, above the $0.24 analyst consensus and up from $0.25 a year earlier. Amneal Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year revenue guidance was raised. Management now expects 2026 revenue of $3.1 billion to $3.2 billion, compared with a prior outlook near $3.1 billion, suggesting continued confidence in demand and operating performance. AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised
• Positive Sentiment: Debt repricing should reduce interest expense. The company completed a July debt repricing, which is expected to lower borrowing costs and support future earnings and cash flow. Amneal Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: EPS guidance was broadly in line with consensus. Amneal forecast 2026 EPS of $0.96 to $1.06 versus the $0.97 consensus estimate. While the midpoint is slightly above expectations, the range does not represent a major upward revision.
• Negative Sentiment: Investors may be taking profits after the earnings-driven rally. The strong quarterly beat and revenue outlook improvement were likely already reflected in the stock after its recent advance, leaving limited upside when full-year earnings guidance was only modestly better than expectations. Amneal beats expectations in strong Q2 2026

Analysts Set New Price Targets

Several equities research analysts have commented on AMRX shares. Zacks Research lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. UBS Group lifted their price objective on Amneal Pharmaceuticals from $19.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Barclays boosted their target price on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a report on Wednesday, May 20th. The Goldman Sachs Group reissued a “buy” rating and set a $21.00 target price on shares of Amneal Pharmaceuticals in a research report on Friday. Finally, Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Amneal Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $17.33.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.